Gamma knife radiosurgery is effective in patients with thyrotropin-secreting pituitary adenomas

• Published in: Journal of endocrinological investigation 2024-08, Vol.47 (8), p.1923-1930
• Main Authors: Losa, M., Albano, L., Barzaghi, L. R., Bailo, M., Mortini, P.
• Format: Article
• Language: English
• Subjects: Adenoma; Adenoma - metabolism; Adenoma - pathology; Adenoma - surgery; Adult; Aged; Drug therapy; Endocrinology; Female; Follow-Up Studies; Humans; Hyperthyroidism; Hypogonadism; Internal Medicine; Male; Medical treatment; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Original Article; Patients; Pituitary; Pituitary Neoplasms - metabolism; Pituitary Neoplasms - surgery; Radiosurgery; Radiosurgery - methods; Remission; Retrospective Studies; Somatostatin; Thyroid-stimulating hormone; Thyrotropin - blood; Thyrotropin - metabolism; Treatment Outcome; Tumors
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-023-02291-1

Purpose Thyrotropin ( TSH)-secreting pituitary adenoma (TSHoma) is a rare cause of TSH-dependent hyperthyroidism. The first therapeutic option is surgery. Medical treatment with somatostatin analogs is also effective. To obviate the need for lifelong drug therapy, gamma knife radiosurgery (GKRS) might be considered in selected patients. We report the largest series of patients with TSHoma treated by GKRS at a single center. Methods This study was a retrospective analysis of 18 consecutive patients with TSHoma treated by GKRS between 1994 and 2022. Normalization of hyperthyroidism, when present at the time of surgery, and control of tumor growth were the main outcomes of the study. Results The median follow-up after GKRS treatment was 114 months (IQR, 57–213 months; range 17–285 months). No patients had growth of the residual tumor after GKRS. Remission of hyperthyroidism occurred in 9 of the 11 (81.8%) patients who were hyperthyroid before GKRS. The probability of hyperthyroidism remission three years after GKRS was 59.1% (95% CI 27.9–90.3%). No major side effects occurred after GKRS. One patient out of the 15 patients (6.7%) with normal baseline adrenal function and follow-up longer than 3 years developed new onset hypoadrenalism, while hypogonadism did not occur in the 13 patients with baseline normal function. Conclusion Our study shows that GKRS is an effective and safe adjuvant treatment for selected patients with residual or recurring TSHoma. The option of GKRS as an alternative treatment to lifelong medical treatment with somatostatin analogs should be thoroughly discussed with the patients.